ENTRY       D12182                      Drug
NAME        Rozanolixizumab (USAN/INN);
            Rozanolixizumab (genetical recombination) (JAN);
            rozanolixizumab-noli;
            Rystiggo (TN)
PRODUCT     RYSTIGGO (UCB)
FORMULA     C6462H9984N1704O2016S44
EXACT_MASS  145119.8822
MOL_WEIGHT  145209.4836
SEQUENCE    (Heavy chain)
            EVPLVESGGG LVQPGGSLRL SCAVSGFTFS NYGMVWVRQA PGKGLEWVAY IDSDGDNTYY
            RDSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCTTGI VRPFLYWGQG TLVTVSSAST
            KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
            SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
            PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV
            SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV
            SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF
            SCSVMHEALH NHYTQKSLSL SLGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCKSSQSLV GASGKTYLYW LFQKPGKAPK RLIYLVSTLD
            SGIPSRFSGS GSGTEFTLTI SSLQPEDFAT YYCLQGTHFP HTFGQGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H131-L219, H144-H200, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'131-L-219, H'144-H'200, H'258-H'318, H'364-H'422, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
REMARK      Therapeutic category: 6399
            Product: D12182<JP/US>
EFFICACY    Autoimmune disease treatment, Anti-Fc receptor antibody
  DISEASE   Generalized myasthenia gravis (anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive) [DS:H01594]
  TYPE      Monoclonal antibody
TARGET      FCGRT [HSA:2217] [KO:K24019]
INTERACTION  
BRITE       USP drug classification [BR:br08302]
             Antimyasthenic Agents
              Rozanolixizumab
               D12182  Rozanolixizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D12182  Rozanolixizumab (USAN/INN); Rozanolixizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Immune system
                FCGRT
                 D12182  Rozanolixizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12182
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12182
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12182
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D12182
DBLINKS     CAS: 1584645-37-3
///
